Search

Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.

… The focus of the Cheng laboratory is to elucidate the molecular mechanisms of cell death with an overarching goal of directly translating cell death mechanisms into novel anti-cancer therapeutic strategies that can effectively trigger cancer cell death and enhance anti-cancer immunity. Emily H. Cheng

Computational biologist Dana Pe’er combines single-cell and spatial profiling technologies with machine learning approaches to address fundamental questions in gene regulation, cellular plasticity and cell-cell communication in the contexts of cancer, immunity and development.

… The Pe’er lab is an interdisciplinary group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science. Empowered by potent technologies such as single-cell genomics and imaging-based molecular profiling, we analyze complex data to understand

Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.

… Research in the laboratory focuses on the discovery and characterization of novel cancer predisposing genes in humans, including both common and rare variants. We conduct studies to describe phenotype, penetrance, modifying effect, and clinical outcomes associated with germline genetic alterations in

Physician-Scientist A. Ari Hakimi, MD studies genetic and metabolic mechanisms of immune response in kidney cancers.

… The Hakimi Lab aims to understand immune infiltration, inflammation, and the tumor microenvironment in RCC to identify novel therapeutic targets to overcome resistance to systemic therapies. These studies apply bulk, single-cell and spatial RNA sequencing, flow cytometry, and immunogenomic analyses to

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.

… The focus of the Berger laboratory is to use novel computational and experimental techniques to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response. The identification of molecular drivers of cancer and the development

Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung and pancreatic cancers.

… The Tammela lab is interested in understanding the remarkable phenotypic heterogeneity of cancer cells within tumors. We approach this question using a combination of sophisticated genetically engineered mouse models, single-cell approaches, tracing and ablation of distinct tumor cell lineages, CRISPR-mediated

The Studer laboratory investigates human stem cells as tools to understand normal and pathological development in the nervous system and to develop cell-based strategies for regenerative medicine.

… Our laboratory aims at exploiting recent advances in stem cell biology to develop radically new therapies for degenerative disease and cancer. The main focus in the lab is on the biology and application of human embryonic stem (ES) and human induced pluripotent (iPS) cells. Pluripotent stem cells can

The Baylies laboratory studies the mechanisms that form and maintain muscle both during normal development and in disease.

… Developmental biologist Mary Baylies studies the mechanisms that form and maintain muscle both during normal development and in disease.   Mary Baylies, PhD Professor PhD, The Rockefeller University Achievements Identified that global, regional, and local inputs contribute to nuclear size regulation

Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.

… Our lab studies the mechanism of eukaryotic chromosome replication. Chromosomes are the carriers of the genetic and epigenetic information and faithful chromosome replication is of fundamental importance for genome maintenance during normal cell proliferation. We employ fully reconstituted yeast and

Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

… Soft tissue sarcoma is a heterogeneous disease with more than 50 histological subtypes, which have diverse biological behavior and – in many cases – unique genetics. Many sarcoma subtypes respond poorly to chemotherapy, so there is an urgent need for better treatment options for patients whose disease